TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9708081

Group type: EXPERIMENTAL
Intervention: Biopatch dressing (Johnson & Johnson Medical Inc.) used for insertion-site management of CVCs
Number of subjects: 33

Group type: COMPARATOR
Intervention: Opsite IV 3000 alone (control group)
Number of subjects: 33
Study: 8560598

Group type: EXPERIMENTAL
Intervention: R‐ORS (50 g/L)
Number of subjects: 79

Group type: COMPARATOR
Intervention: G‐ORS
Number of subjects: 79
Study: 1537131

Group type: EXPERIMENTAL
Intervention: Fish oil (2.7 g/day of eicosapentaenoic acid, 1.8 g/day of docosahexaenoic acid)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Dietary intake of omega-3 fatty acids > 0.15 g/day
Number of subjects: 205
Study: 6147905

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 90
Study: 31316037

Group type: EXPERIMENTAL
Intervention: Hangekobokuto (HKT)
Number of subjects: 34
Study: 28593748

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injectable hydromorphone
Number of subjects: 0
Study: 27622998

Group type: EXPERIMENTAL
Intervention: Diuretic therapy (DT) with midodrine and rifaximin (n=400)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Diuretic therapy (DT) only (n=200)
Number of subjects: 600
Study: 24357105

Group type: EXPERIMENTAL
Intervention: Brussels sprouts (high glucobrassicin concentration)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cabbage (low glucobrassicin concentration)
Number of subjects: 25
Study: 22632139

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention consisting of four sessions of motivational interviewing (MI) and cognitive behavioural therapy (CBT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 160
Study: 19361872

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg administered three times daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 18162561

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 25
Study: 15860914

Group type: EXPERIMENTAL
Intervention: Early supported discharge (ESD)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Acute stroke unit care combined with ESD
Number of subjects: 320

Group type: COMPARATOR
Intervention: Traditional stroke care
Number of subjects: 320
Study: 12527975

Group type: EXPERIMENTAL
Intervention: Even pacing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Negative pacing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Positive pacing
Number of subjects: 9
Study: 10659099

Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 8087261

Group type: EXPERIMENTAL
Intervention: Monostrut (MS)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Medtronic-Hall (MH)
Number of subjects: 403
Study: 2625616

Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic (Phenyltrope)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tropicamide 1% alone
Number of subjects: 0
Study: 857369

Group type: EXPERIMENTAL
Intervention: Dextran 70 (2 X 500 ml i.v.)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study: 31327083

Group type: EXPERIMENTAL
Intervention: Local application of doxycycline-loaded PLGA nanospheres (DOXY)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Local application of placebo PLGA nanospheres (PLAC)
Number of subjects: 40
Study: 31188437

Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose-enriched inulin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 28592037

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii 500 mg twice a day for 21 days
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 163
Study: 26288285

Group type: EXPERIMENTAL
Intervention: APTPA (500 mg glucosamine hydrochloride and 500 mg chondroitin sulfate) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: APTPA (1 tablet twice a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) + melaxen (3 mg melatonin 30-40 min before sleep)
Number of subjects: 178

Group type: COMPARATOR
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: APTPA (1 tablet twice a day) + diclofenac (25 mg 2-3 times a day) without melaxen
Number of subjects: 178
Study: 23131463

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Complication Scale (PFCS)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Modified Clavien‐Dindo scores
Number of subjects: 977
Study: 21396091

Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal pessaries (100 mg) for 6 days
Number of subjects: 3208

Group type: COMPARATOR
Intervention: Usual care (no treatment, routine antenatal care)
Number of subjects: 3208
Study: 18287162

Group type: EXPERIMENTAL
Intervention: Oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral treatment only (same dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light elastic compression stockings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals without treatment (control group)
Number of subjects: 0
Study: 16844506

Group type: EXPERIMENTAL
Intervention: Mole-mapping diagram
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no diagram)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mole-mapping diagram (altered images)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (altered images)
Number of subjects: 88
Study: 12787117

Group type: EXPERIMENTAL
Intervention: Objective measurement of clinical signs
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Published severity scale
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Modified versions of published scales
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Unnamed scales
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patient symptoms
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Disease extent
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Unvalidated outcome measures
Number of subjects: 93
Study: 10770423

Group type: EXPERIMENTAL
Intervention: Prophylactic photopheresis
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (cyclosporine, azathioprine, prednisone without photopheresis)
Number of subjects: 23
Study: 8848847

Group type: EXPERIMENTAL
Intervention: Children with clubfoot
Number of subjects: 21

Group type: COMPARATOR
Intervention: Children without deformity (control group)
Number of subjects: 21
Study: 8403911

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (Cu IUD)
Number of subjects: 0
Study: 3512619

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 0.5 mg/kg/d
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 15 mg/kg/d
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 0.5 mg/kg/d and 15 mg/kg/d
Number of subjects: 10

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 10
Study: 29621284

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 198

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 198
Study: 27538952

Group type: EXPERIMENTAL
Intervention: Xinyue capsules (1.8 g/day, three times daily for up to 24 weeks)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo capsules (three times daily for up to 24 weeks)
Number of subjects: 1100
Study: 25431770

Group type: EXPERIMENTAL
Intervention: 8 g/day essential amino acids (EAAs); n=19
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isocaloric placebo (maltodextrin); n=19
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls; n=8
Number of subjects: 38
Study: 22209126

Group type: EXPERIMENTAL
Intervention: telephone-delivered collaborative care intervention for depression
Number of subjects: 302

Group type: COMPARATOR
Intervention: usual care by primary care physicians
Number of subjects: 302
Study: 20449532

Group type: EXPERIMENTAL
Intervention: Low-protein dietetic foods
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 49
Study: 17449306

Group type: EXPERIMENTAL
Intervention: Neramexane (40 mg p.o.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15946202

Group type: COMPARATOR
Intervention: Prophylactic doses of nadroparin (2850 a‐Xa IU)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Therapeutic doses of nadroparin (body-weight adjusted)
Number of subjects: 164
Study: 12891111

Group type: EXPERIMENTAL
Intervention: Self-administered WIQ
Number of subjects: 60

Group type: COMPARATOR
Intervention: Telephone-administered WIQ
Number of subjects: 60
Study: 10335905

Group type: EXPERIMENTAL
Intervention: (S)-propranolol 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (S)-atenolol 50 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R)-propranolol 40 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R)-atenolol 50 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R,S)-carvedilol 25 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R,S)-verapamil 120 mg
Number of subjects: 15
Study: 8724530

Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) 75 mg/m2/day x 4 plus continuous infusion high-dose cytarabine (CIHDAC) 1.5 g/m2/day x 4
Number of subjects: 204

Group type: COMPARATOR
Intervention: Continuous infusion high-dose cytarabine (CIHDAC) alone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Amsacrine (AMSA) plus CIHDAC
Number of subjects: 204
Study: 1748254

Group type: EXPERIMENTAL
Intervention: Diet-plus-exercise (upper-arm exercise)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet (control group)
Number of subjects: 20
Study: 6137327

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (4-week period)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Indapamide (used alone or in combination)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 26
Study: 31821355

Group type: EXPERIMENTAL
Intervention: 2.0% non-chemically modified sodium hyaluronate (SH)
Number of subjects: 292

Group type: COMPARATOR
Intervention: 0.8% hylan G-F 20 (control)
Number of subjects: 292
Study: 29916110

Group type: EXPERIMENTAL
Intervention: Intravenous carbetocin (100 mcg)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Intravenous oxytocin (5 U)
Number of subjects: 350
Study: 26399485

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 53
Study: 24769332

Group type: EXPERIMENTAL
Intervention: AXT914 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AXT914 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide (20 μg Forteo/PTH(1-34) fragment)
Number of subjects: 0
Study: 21701082

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg daily, n=24)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Aspirin (100 mg daily, n=25)
Number of subjects: 49
Study: 19493295

Group type: EXPERIMENTAL
Intervention: Internet-based sex therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 98
Study: 17470830

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg of body weight)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 15138905

Group type: EXPERIMENTAL
Intervention: Stimulating catheter-guided perineural placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonstimulating catheter placement
Number of subjects: 20
Study: 11510062

Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (+) combined with CEA
Number of subjects: 108

Group type: COMPARATOR
Intervention: i.v.‐PCA (‐)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: i.v.‐PCA (+)
Number of subjects: 108
Study: 9669006

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study: 7834003

Group type: EXPERIMENTAL
Intervention: 5-mL saline instillation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Suction catheter insertion
Number of subjects: 10
Study: 3239468

Group type: EXPERIMENTAL
Intervention: Hunger factor
Number of subjects: 0
Study: 29915435

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention using wearable monitoring devices with IoT systems and monthly remote health guidance from a public health nurse.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 145
Study: 28628763

Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Depression (D-MCT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Active control intervention (walking and psychoeducation sessions)
Number of subjects: 154
Study: 26420199

Group type: EXPERIMENTAL
Intervention: Nutritional intervention focusing on education to increase dietary intake of whole grain, vegetables, and fruits, and to reduce sodium, simple sugar, and dietary fat (especially cooking oil and pork lard).
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (same as above).
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 235
Study: 23190777

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 0
Study: 21911890

Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet (LCD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low Fat Diet (LFD)
Number of subjects: 59
Study: 18608135

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 16567711

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study: 12620952

Group type: EXPERIMENTAL
Intervention: Bronchodilator premedication (albuterol or ipratropium)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Preoperative capnometry
Number of subjects: 109
Study: 10695689

Group type: EXPERIMENTAL
Intervention: Low-dose antihypertensive therapy
Number of subjects: 3975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3975
Study: 9350317

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8461472

Group type: EXPERIMENTAL
Intervention: 7 g/d of a 85% omega-3 fatty acid fish oil concentrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (7 volunteers)
Number of subjects: 14
Study: 3026009

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin (1 g of sulbactam and 2 g of ampicillin three times a day for two weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cefotaxime (2 g three times a day for two weeks)
Number of subjects: 22
Study: 29199784

Group type: EXPERIMENTAL
Intervention: Individual counselling sessions via videoconferencing calls
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Wearable PA monitors
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 29803269

Group type: EXPERIMENTAL
Intervention: BLISS (modified Baby-Led Weaning)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 206
Study: 26289058

Group type: EXPERIMENTAL
Intervention: Educational video on breastfeeding
Number of subjects: 522

Group type: COMPARATOR
Intervention: Educational video on prenatal nutrition and exercise
Number of subjects: 522
Study: 24705018

Group type: EXPERIMENTAL
Intervention: Special whey protein bar (1:1 carbohydrate to protein ratio)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Commercially available tomato juice
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study: 22146812

Group type: EXPERIMENTAL
Intervention: Expandable pedicle screws (EPS)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional pedicle screws (CPS)
Number of subjects: 157
Study: 20422202

Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Imaging (THI)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Conventional B-scan (BSCAN)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Compound Imaging (CI)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Tissue Harmonic Compound Imaging (THICI)
Number of subjects: 313
Study: 17208334

Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 3010
Study: 15076782

Group type: EXPERIMENTAL
Intervention: Foot cooling (FC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No foot cooling (NC)
Number of subjects: 12
Study: 12460519

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormones (rhGH) 9 U/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 24
Study: 9808825

Group type: EXPERIMENTAL
Intervention: Tailored counseling and guide (Pathways to Freedom)
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Standard counseling and guide (Clearing the Air)
Number of subjects: 1422
Study: 7700763

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day intravenously for 3 days, 0.25 mg/kg/day for 3 days, and 0.1 mg/kg/day for 1 day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 2199618

Group type: EXPERIMENTAL
Intervention: Chemotherapy (six IV cyclophosphamide, methotrexate, and fluorouracil courses followed by four IV epirubicin courses)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years treatment)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Tamoxifen
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Chemotherapy (with or without tamoxifen)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 510
Study: 276963

Group type: EXPERIMENTAL
Intervention: Xylocitin with adrenalin (1:80 000)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylocitin with noradrenalin (1:20 000)
Number of subjects: 0
Study: 31112273

Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study: 28374695

Group type: EXPERIMENTAL
Intervention: Cytoflavin 10 ml/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cytoflavin 20 ml/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 86
Study: 25888067

Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of docetaxel + sunitinib
Number of subjects: 18
Study: 23418985

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 22
Study: 21421600

Group type: EXPERIMENTAL
Intervention: Immediate percutaneous coronary intervention (PCI) strategy
Number of subjects: 352

Group type: COMPARATOR
Intervention: Delayed PCI strategy (next working day)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Patients with major bleeding
Number of subjects: 352

Group type: COMPARATOR
Intervention: Patients without major bleeding
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 352
Study: 19216685

Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional follow-up (n = 18)
Number of subjects: 35
Study: 17659845

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (without PCOS)
Number of subjects: 457
Study: 16042327

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GHTX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-treatment group (NonTX)
Number of subjects: 32
Study: 12476037

Group type: EXPERIMENTAL
Intervention: 800-mg oral dose of telithromycin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous infusion of 400 mg telithromycin (young) or 480 mg telithromycin (elderly)
Number of subjects: 24
Study: 10731130

Group type: EXPERIMENTAL
Intervention: Tazarotene plus mid- or high-potency topical corticosteroid
Number of subjects: 698

Group type: COMPARATOR
Intervention: Tazarotene plus placebo
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Tazarotene alternating with high-potency topical corticosteroid
Number of subjects: 698

Group type: COMPARATOR
Intervention: Tazarotene alternating with mid-potency corticosteroid
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Tazarotene plus low-, mid-, and high-potency corticosteroid
Number of subjects: 698
Study: 8525815

Group type: COMPARATOR
Intervention: Conventional running shoes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Running shoes with a negative sole
Number of subjects: 35
Study: 2024970

Group type: EXPERIMENTAL
Intervention: Chloroquine and proguanil (Ch-P)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 130